Position in SYRE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$8,413,059
+$4,119,556 QoQ
Shares Held
94,763
+11.3% QoQ
Ownership
0.107%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#78
of 266 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 23%
Shared 0%
None 77%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. SYRE ranks #32 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in SYRE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,413,059 | 94,763 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $4,293,503 | 85,121 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $2,717,638 | 82,956 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,188,518 | 70,914 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $1,095,324 | 73,168 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $903,931 | 56,023 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $1,342,254 | 57,657 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $1,586,228 | 53,935 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,220,074 | 51,896 | Shares | Sole | 2024-08-01 | |
| No filing history on record for this holder in this stock. | ||||||